By: IPP Bureau
Last updated : December 03, 2025 12:05 pm
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Global biopharma giant AbbVie has announced that its pivotal Phase 3 ECLIPSE study of atogepant (60 mg) for the acute treatment of migraine in adults has met its primary and key secondary endpoints, showing significant improvement over placebo.
The results, which will be presented as a late-breaking study at the European Headache Congress in Lisbon, demonstrate atogepant’s ability to provide rapid pain relief and freedom from the most bothersome migraine symptoms.
"These latest ECLIPSE results mark a step forward in helping more people living with migraine achieve pain freedom and underscores our commitment to addressing unmet needs in acute migraine care," said Primal Kaur, senior vice president, immunology, neuroscience, eye care and specialty development at AbbVie.
"With our submission to the European Medicines Agency, AbbVie remains dedicated to broadening treatment choices for patients. If approved, atogepant would offer a new acute treatment option for migraine attacks in Europe."
In the randomized, double-blind, placebo-controlled study, 24.3% of patients receiving atogepant achieved pain freedom two hours after treatment of their first migraine attack, compared with 13.1% on placebo. Twelve of sixteen key secondary endpoints were also met, including freedom from the most bothersome migraine symptom at two hours.
"Migraine is a highly debilitating disease with a profound impact on daily life. Despite available therapies, many people still encounter barriers to effective, flexible treatment," said Annelies Van Dycke, neurologist, ECLIPSE investigator, and head of neurology at AZ Sint-Jan, Bruges, Belgium.
"Providing access to targeted treatments such as atogepant within integrated care plans has the potential to make a meaningful difference in the lives of patients with migraine."
The study confirmed atogepant’s safety profile over a 24-week treatment period, consistent with prior preventive migraine studies. No new safety signals were observed. The most common treatment-emergent adverse events were nasopharyngitis (4.6%) and upper respiratory tract infection (2.3%).